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The production of megakaryocytes (MKs)—the precursors of blood platelets—from human
pluripotent stem cells (hPSCs) offers exciting clinical opportunities for transfusion medicine.
Here we describe an original approach for the large-scale generation of MKs in chemically
deﬁned conditions using a forward programming strategy relying on the concurrent
exogenous expression of three transcription factors: GATA1, FLI1 and TAL1. The forward
programmed MKs proliferate and differentiate in culture for several months with MK purity
over 90% reaching up to 2 105 mature MKs per input hPSC. Functional platelets are
generated throughout the culture allowing the prospective collection of several transfusion
units from as few as 1 million starting hPSCs. The high cell purity and yield achieved by MK
forward programming, combined with efﬁcient cryopreservation and good manufacturing
practice (GMP)-compatible culture, make this approach eminently suitable to both in vitro
production of platelets for transfusion and basic research in MK and platelet biology.
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egakaryocytes (MKs) generate blood platelets whose
primary role is to stop haemorrhages via localized clot
formation at the site of vessel injury1,2. MKs are
polyploid cells derived from haematopoietic stem cells residing in
the bone marrow where they represent only 0.01% of the total
nucleated blood cells. By extension of cytoplasmic protrusions
through bone marrow sinusoids, they release daily B1 1011
platelets into the blood stream to sustain the count of short-lived
(7–10 days) circulating platelets between 150–450 109 per litre
of blood3,4. A decrease in platelet number, or thrombocytopenia,
may occur following bone marrow failure (inherited or acquired,
such as post-cancer treatment) or severe peripheral bleeding after
trauma or surgery, and potentially leads to life-threatening
haemorrhages. Currently, prophylactic and therapeutic treatment
essentially relies on transfusion of ABO and Rhesus-D-matched
platelet concentrates—at 42.4 1011 platelets per unit—from
voluntary donations5,6. Recently, the increase in high-dose cancer
therapy, advanced surgical procedures and the ageing population
has led to a rising demand for platelets with over 4.5 million
platelet units transfused per year in Europe and the United
States7. In addition, platelet transfusion refractoriness in
HLA class I alloimmunized chronically transfused patients and
multiparous women necessitates the special provision of matched
platelet units sourced from a small pool of genotyped recallable
donors8. Altogether, the dependence on donations combined
with the limited shelf life of platelet concentrates (5–7 days)
represents a logistical, ﬁnancial and biosafety challenge for health
organizations worldwide.
Human pluripotent stem cells (hPSCs)—including embryonic
stem cells (hESCs) derived from embryos and induced PSCs
(hiPSCs) generated from post-natal somatic cells—can be
maintained in vitro for prolonged periods while retaining
the capacity to differentiate towards virtually any cell type
upon adequate stimulation9–11. Therefore, they offer huge
opportunities for basic research and clinical applications12. The
production of platelets in vitro from genetically deﬁned hPSC
lines could revolutionize transfusion medicine by providing a
controllable source of platelets13. Moreover, platelets are
anucleate and do not proliferate which means they can be
irradiated before transfusion. This provides a marked safety
advantage over other hPSC-derived therapeutic cells which can
potentially retain oncogenic cell fractions14. However, in vitro
systems for the production of large amounts of MKs and
subsequent platelet release to match the needs for making
transfusion units still require considerable optimization.
Our work describes a novel approach for generating large
quantities of functional MKs from hPSCs with unique advantages
for clinical development. Existing protocols have so far relied on
external signals provided by cytokines or stromal cells to mimic
embryonic development in vitro and thus direct sequential
differentiation of hPSCs into MKs, a process designated as
‘directed differentiation’15–20. While mature MKs showing
functional platelet release are produced, this strategy has been
limited by the relatively low number of MKs generated or by the
complex genetic modiﬁcations and clonal selection required to
immortalize MKs post differentiation. Urged by the recent
discoveries on the plasticity of cell identities controlled by
limited sets of transcription factors (TFs)21, we adopted a
radically different approach for the generation of MKs by
exploring the potential of exogenous TFs to drive the
differentiation process from hPSCs, a strategy called ‘forward
programming’ (FOP). Proceeding from a methodically curated
list of candidate genes, we discovered that the combination of
GATA1–FLI1–TAL1 uniquely promoted highly efﬁcient MK-
FOP from an array of hPSC lines in chemically deﬁned
conditions. Critically, the forward programmed MKs (fopMKs)
matured into platelet-producing cells that could be cryopreserved,
maintained and ampliﬁed in vitro for over 90 days showing
an average yield of 200,000 MKs per input hPSC.
This unprecedented efﬁciency combined with minimal cell
manipulation and low cytokine requirements makes MK-FOP a
promising platform for basic research as well as future clinical
applications in the ﬁeld of transfusion medicine.
Results
GATA1–FLI1–TAL1 induces hPSC to MK commitment. Based
on the knowledge that cooperative binding of TFs to target sites
can activate gene expression in repressed chromatin22, we
hypothesized that MK-speciﬁc TFs forming complexes able to
interact with chromatin remodelers would be able to rewire the
hPSC gene regulatory network to induce MK-FOP. We compared
TF expression in the H9 hESC line and cord blood-derived
megakaryocytes (cbMKs)23 and narrowed down to a list of 46 TF
candidates subsequently ranked based on differential gene
expression level and reported protein interactions between
candidates and epigenome modiﬁers using VisANT24 (see
Supplementary Fig.1 and Methods for details). Nine TFs from
the top 20 candidates were individually cloned into a lentiviral
vector backbone under the control of an EF1a promoter to assess
their MK-FOP potential (Fig. 1a).
H9 cells were transduced concurrently with equal amounts of
each lentiviral vector and subsequently maintained in hPSC
medium (FGF2þActivin-A) for 2 days followed by MK medium
(thrombopoietin (TPO)þ SCF (stem cell factor)) for a further 5
days. The transduction efﬁciency measured with a green
ﬂuorescent protein (GFP) reporter vector was 60.3±5.6% in
these conditions (n¼ 4). Transduction with nine TFs generated a
well-deﬁned population of cells expressing CD41a (integrin
alpha-IIb: ITGA2B) on day 7 (1.1±0.6%; Fig. 1b). In an attempt
to identify the critical TFs responsible for the generation of this
population expressing the marker typically associated with MK
lineage commitment, CD41aþ cells were sorted and transgene
expression measured by RT-qPCR (quantitative PCR with reverse
transcription). Intriguingly, we detected a striking bias for
GATA1, FLI1 and TAL1 (hereafter ‘3-TFs’) transgene expression
in the CD41aþ population compared with its negative
counterpart which suggested their instrumental role in the
acquisition of the CD41a phenotype (Fig. 1b). Accordingly, the
3-TF combination tested in two hiPSC lines generated more
CD41aþ cells compared with all nine TFs together demonstrat-
ing its superior efﬁciency (2.5±0.04% versus 0.2±0.04%
respectively; Fig. 1c). We assessed all permutations of the 3-TFs
and showed that the maximum CD41aþ cell yield was achieved
upon concurrent transduction of the 3-TFs which also correlated
with a higher clonogenic potential (Fig. 1d; Supplementary
Fig. 2a). Importantly, no CD41aþ cells were detected after
transduction with a GFP control vector demonstrating that
culture conditions were not inductive per se (Fig. 1d). Finally, we
combined the 3-TFs using a single lentiviral vector carrying a
polycistronic expression cassette encoding for the 3-TFs and a
GFP reporter. Virtually all GFP-positive cells differentiated into
CD41aþ cells by day 7, conﬁrming the efﬁcacy of the 3-TFs in
inducing MK-FOP (Supplementary Fig. 2b).
Additional analyses conﬁrmed that the emerging CD41aþ
population at day 7 truly represented early MK lineage
commitment. We ﬁrst showed that the expression of key MK
genes including MPL (coding for the TPO receptor), the TFs
ZFPM1, RUNX1, NFE2 as well as the endogenous expression of
GATA1, FLI1 and TAL1 were speciﬁcally induced in the
CD41aþ cell population (Fig. 1e). Moreover, the MK clonogenic
potential was exclusively retained in the CD41aþ cell population
which further developed to mature MK colonies expressing
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CD42b (glycoprotein-Ib: GPIBA) functionally demonstrating
MK commitment (Fig. 1f,g). Altogether, we thereby identiﬁed
GATA1, FLI1 and TAL1 as a minimal and sufﬁcient combination
of TFs to induce the formation of MK precursors from hPSCs.
Chemically deﬁned MK-FOP generates high purity MK cultures.
To facilitate transfer to the clinic, we developed a chemically
deﬁned xeno-free 3-TF MK-FOP protocol. Induction of
mesoderm commitment from hiPSCs by a 2-day exposure to
FGF2, BMP4 and LY-294002 (ref. 25) signiﬁcantly increased
the percentage of CD41aþ cells at day 7 compared with
pluripotency maintenance conditions (5.4±1.6-fold increase;
Supplementary Fig. 3a). Next, we assessed the beneﬁt of using
forced aggregation embryoid body formation instead of the base
two-dimensional (2D) culture. When coupled with mesoderm-
inducing conditions, embryoid body culture further improved the
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Figure 1 | TF candidate screening for MK forward programming. (a) TF expression in hPSCs versus cbMKs plotted as a row normalized heatmap with
indications of recorded TF internal and chromatin modiﬁers node numbers and protein interactions among the top 20 TF candidates reported by VisANT.
The nine experimentally tested TFs are highlighted in red. (b) The H9 hESC line was concurrently transduced with the 9-TFs and maintained in pluripotency
medium (FGF2þActivin-A) for 2 days followed by MK medium (TPOþ SCF) for a further 5 days. CD41aþ cells generated 7 days after lentiviral
transduction (dot plot, mean% ±s.e.m., n¼ 5; FL1: 530/40nm channel) were sorted by ﬂow cytometry and transgene expression levels quantiﬁed by
RT-qPCR (n¼ 1). (c) The percentage of CD41aþ cells was monitored by ﬂow cytometry 7 days after transduction of the hiPSC lines #1 and #2 with the
9-TFs or 3-TFs combination. Bar graphs represent the fold increase of CD41aþ cell count relative to the 9-TFs combination (mean ±s.e.m., n¼4;
**Po0.01 by two-tail t-test). NT: non-transduced cells. (d) The hiPSC#1 line was transduced with all permutations of the 3-TFs and percentages of
CD41aþ cells measured by ﬂow cytometry at day 7. Bar graphs represent the fold increase of CD41aþ cell count relative to the 3-TFs combination (mean
±s.d., n¼ 2; *P¼0.06 and Po0.01 versus Gþ F and other combination respectively by two-tail t-test). G: GATA1, F: FLI1, T: TAL1, GFP: control vector.
(e) The endogenous expression of key MK genes was monitored by RT-qPCR from CD41a ﬂow sorted cells 7 days after transduction of the hiPSC lines #1
and #2 (mean±s.d., n¼ 2). (f) The hiPSC lines #1 and #2 were transduced with the 3-TFs and sorted by ﬂow cytometry for expression of CD41a at day 7.
The clonogenic potential of sorted cells was tested in methylcellulose semi-solid medium supplemented with TPO and SCF. The number of colonies per
5,000 sown cells was determined after 10 days from duplicate wells (mean±s.e.m., n¼4). (g) A representative MK colony obtained from a CD41aþ cell
co-expressing CD41a and CD42b as detected by immunoﬂuorescence is shown (scale bar, 50mm).
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yield of CD41aþ cells at day 7 (5.2±0.9-fold increase;
Supplementary Fig. 3b). The embryoid body culture had the
additional advantage of providing a standardized quantity of
input cells thereby conferring reproducibility. The ﬁnal protocol
combined lentiviral transduction with embryoid body formation
over the ﬁrst 24 h with mesoderm induction for the ﬁrst 2 days.
This protocol allowed consistent transduction efﬁciencies
amongst hiPSC lines (68.2±4.1% using a single GFP control
vector, n¼ 11 using three hiPSC lines), resulting in 22% co-
transduction efﬁciency as estimated using reporter vectors
(Supplementary Fig. 3c). As MK maturation was not optimally
sustained in the low-adherence embryoid body culture setting, we
included a single-cell dissociation step which gave an optimal MK
yield when performed at day 10 post transduction
(Supplementary Fig. 3d) followed by a further 10 day culture in
medium containing TPO and IL1b routinely used for cbMK
differentiation26. The optimized MK-FOP protocol using xeno-
free GMP-grade basal medium and recombinant cytokines is
depicted in Fig. 2a.
We observed a gradual increase in CD41aþ cells from day 4
post transduction followed by the acquisition of the mature MK
marker CD42a (glycoprotein IX:GP9, component of the Von
Willebrand platelet receptor complex) from day 6 onwards
mimicking cbMK differentiation (Fig. 2b; Supplementary Fig. 3e).
Critically, using two different hiPSC lines, MK-FOP consistently
achieved MK lineage purity (495% CD41aþ cells) by day 15
post transduction with 450% CD42aþ mature MKs by day 20
(Fig. 2b). A robust cell expansion during the single-cell culture
step led to the generation of large quantities of MKs with up to
28.4±7.8-fold increase relative to the hiPSC input at day 20
(iPSC#1, n¼ 14; Fig. 2c). Interestingly, MK-FOP achieved
signiﬁcantly higher cell yields compared with a standard
MK-directed differentiation approach27, producing in our
hands on average 26.3 and 11.7 times more mature MKs from
the hiPSC lines #1 and #2, respectively (Fig. 2c). In addition, the
MK purity obtained by MK-FOP was signiﬁcantly higher than
MK-directed differentiation (97.7±0.8% versus 21.3±2.9%,
respectively; Supplementary Fig. 3f).
To further assess the MK identity of FOP cells, day 20 fopMKs
were compared with day 10 cbMKs as a benchmark. At this stage,
both cultures show similar MK maturity (50–60% CD42aþ cells;
Fig. 2b; Supplementary Fig. 3e). The key platelet surface receptors
for ﬁbrinogen (aIIb-b3), Von Willebrand factor (gpIb-V-IX) and
collagen (gpVI) were readily detected in both cultures (Fig. 2d).
Morphologically, fopMK cultures displayed a typical mix of
megakaryoblasts with large peripheral nuclei and mature MKs
with increased cytoplasmic volume and frequent polyploid cells
similarly to cbMK cultures (Fig. 2e,f). In accordance with
published results for in vitro-derived neonate and hPSC
MKs17,28, the cell ploidy remained low on average and was
comparable for both fopMKs and cbMKs (o2% 8N cells;
Supplementary Fig. 3g). Analysis of the fopMK ultrastructure
by electron microscopy showed lobulated nuclei, developing
demarcation membrane system (cytoplasmic cell membrane
supply for platelet release), cytoplasmic multi-vesicular bodies
(precursors to platelet granules) and mature granules (Fig. 2g).
We conﬁrmed by confocal microscopy that major alpha-granule
proteins (P-selectin, thrombospondin, ﬁbrinogen and vWF) were
indeed correctly expressed and patterned in fopMKs (Fig. 2h).
Importantly, the total expression level of the 3-TFs in fopMKs—
as sum of transgenic and endogenous expression—was not
signiﬁcantly different from cbMKs (Supplementary Fig. 3h).
Collectively, these data demonstrate the efﬁcient production and
maturation of MKs derived by forward programming in
xeno-free chemically deﬁned conditions.
MK-FOP produces expandable and cryobankable mature MKs.
We found that fopMKs could be maintained in culture and kept
expanding for an extended period of up to 60 days in the
TPOþ IL1b condition described above (Supplementary Fig. 4a–c).
The expression of KIT (the receptor for SCF, an haematopoietic
progenitor pleiotropic cytokine) on a fraction of the cells
suggested the persistence of a progenitor population in MK-FOP
cultures (Supplementary Fig. 4d). This led us to test the
continuous supplementation with SCF (50 ngml 1)—instead of
IL1b originally used through the second step of culture—in an
attempt to improve further long-term maintenance. In addition,
we reasoned that the high TPO level (100 ngml 1) may not be
required in the MK-FOP context where differentiation was
sustained internally by expression of the 3-TFs, and indeed high
TPO may be responsible for precocious exhaustion of MK-FOP
cultures by over stimulation of differentiation. Consequently, we
tested a lower TPO concentration (20 ngml 1) in combination
with SCF through the second step of MK-FOP (Fig. 3a). In these
conditions, we were able to maintain fopMKs in culture with
steady proliferation for at least 90 days, achieving close to an
average 200,000 MK yield per input hiPSC (1.94±1.59 105,
n¼ 7 for hiPSC#1 and #3 cumulatively; Fig. 3b). This was in
striking contrast with the maximum 1,300 MK fold increase,
earlier loss of CD42a expression and cell viability in long-term
culture using the original high TPO and IL1b condition
(Supplementary Fig. 4a–c). The MKs harvested from optimized
long-term cultures (430 days, deﬁned thereafter as LT-fopMKs)
maintained a purity of over 90% CD41aþ cells with levels of
CD42a expression 460% (Fig. 3c–e) and an increase in late
Figure 2 | Generation of mature MKs by forward programming using chemically deﬁned conditions. (a) Schematic representation of the optimized
MK-FOP protocol. Viral transduction at day 0 concurrent with embryoid body generation and mesoderm induction for 2 days was followed by a period of
culture in an MK induction medium (TPOþ SCF) for 8 days. Embryoid bodies showing cystic structures and actively growing cell aggregates were
dissociated to single cells at day 10 and further differentiated to mature MKs (TPOþ IL1b) until day 20 post transduction. (b) Time course of fopMK
differentiation showing MK lineage commitment (%CD41aþ cells) and MK maturation (%CD42aþ cells) from whole culture (mean±s.e.m. from hiPSC
lines #1 and #2; n¼ 2 (day0–10); n¼6 (day14–22)). Representative ﬂow cytometry dot plots for CD41a and CD42a expression are shown below. (c) The
MK fold increase at day 20 relative to the day 0 hiPSC input is shown on a logarithmic scale for the hiPSC lines #1–4 differentiated by forward programming
(fopMK: mean±s.e.m.; n¼ 14, 7, 3, 5 respectively) or directed differentiation (hiPSCs#1 and #2; ddMK: mean±s.e.m.; n¼ 3,2 respectively). **Po0.01 and
*Po0.05 by two-tail t-test. (d) Representative histograms of the expression of major platelet receptors detected by ﬂow cytometry are shown for day 20
fopMKs (red line) and day 10 cbMKs (blue line) against isotype control (grey shade). (e) The morphology of day 20 fopMKs and day 10 cbMKs was
analysed by modiﬁed Romanowsky staining on ﬁxed cells. Arrowheads point to multinucleated cells. Scale bars, 25mm. (f) Cell size distribution from
fopMK and cbMK cultures is shown as box plots: centre lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5
times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots (n¼ 50, 74 respectively; **Po0.01 by two-tail t-test).
(g) Cell ultrastructure of fopMKs and cbMKs was visualized by transmission electron microscopy. dms, demarcation membrane system; gr, granules;
mvb, multi-vesicular body; mit, mitochondria. Scale bars, 2 mm. (h) Representative confocal pictures of fopMKs immunostained for major alpha-granule
proteins (thrombospondin, ﬁbrinogen, P-selectin and Von Willebrand Factor; iPSC#3 fopMKs, day 40). Scale bars, 25mm.
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maturation markers like GPVI (Supplementary Fig. 4e). The
LT-fopMK cultures contained a mixed population of small
megakaryoblasts growing in loose clusters representing the
actively proliferating cell fraction together with larger polyploid
MKs (Fig. 3f–h). Critically, LT-fopMKs were successfully frozen
over a day 21–70 timeframe and subsequently recovered for
further culture and expansion allowing cryobanking of fopMK
batches (Supplementary Fig. 4f).
We found that LT-fopMK cultures were not immortalized but
ﬁnite with the longest iPSC#1 and iPSC#3 cultures kept for 120
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and 132 days, culminating respectively in 17 million and 800,000
MK fold increases (n¼ 4/5 biological replicate respectively;
Supplementary Fig. 4g). Beyond day 90, most LT-fopMK cultures
showed a drastic loss of cell viability (Supplementary Fig. 4h)
associated with a steady decrease of clonogenic potential and of
CD34þ haematopoietic progenitor content (Supplementary
Fig. 4i,j). At the population level, the average expression of the
3-TFs (sum of endogenous and transgenic expression) in
LT-fopMK cultures was maintained in a close range to day 10
cbMKs (Fig. 3i). Together, we showed the 3-TF-driven MK-FOP
generated a highly proliferative albeit exhaustible progenitor pool
sustaining the expansion of mature MKs in vitro for over 3
months.
Genome-wide analysis conﬁrms long-term MK identity.
We analysed the whole-genome microarray expression data of
MKs derived in vitro by different protocols and from different
stem cell sources: by FOP or directed differentiation from
hiPSCs (fopMKs, LT-fopMKs and ddMKs) and from cbMKs,
all samples with purity greater than 95% CD41aþ and 80%
CD42aþ cells.
First, enrichment analysis using hyperG test (false discovery
rate (FDR) r5%) of gene ontology terms from upregulated genes
versus undifferentiated hiPSC conﬁrmed that MK-FOP efﬁciently
induced the MK phenotype with top biological processes in
fopMKs and LT-fopMKs related to haemostasis/platelet gene
ontology terms as was the case for ddMKs and cbMKs (Fig. 4a).
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This was mirrored by a depletion in differentiation/morphogenesis
gene ontology term-associated genes indicating appropriate down-
regulation of pluripotency features (Fig. 4a). Moreover, the gene set
enrichment analysis29 against a panel of blood cells (cbMKs versus
other blood cells from Haematlas23; n¼ 4 and 46, respectively)
showed speciﬁc enrichment of MK-speciﬁc genes in the list of
genes upregulated in fopMKs further demonstrating the
acquisition of a genuine MK phenotype (normalized enrichment
score (NES)¼ 1.25, FDR¼ 21%; Fig. 4b). The highly similar
expression proﬁles obtained from two distinct hiPSC lines
demonstrates the inter-line qualitative reproducibility of MK-
FOP (r2¼ 0.998 for iPSC#1 and #2; Fig. 4c).
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Differential expression analysis comparing hiPSC-derived MKs
to cbMKs revealed a number of differential expression genes that
were (in accordance with the MK phenotype acquired by
fopMKs) not related to haemostasis/platelet-related biological
processes (503 common, 2,667 total; Z2-fold-change and
FDRr5% cutoff; Fig. 4d). Hierarchical clustering distinguished
the four MK groups while showing a separate cluster encom-
passing the hiPSC-derived MKs (i.e., fopMKs, LT-fopMKs and
ddMKs) distinct from cbMKs indicative of an intrinsic difference
resulting from their hPSC provenance, as previously described30
(Fig. 4e). Interestingly, while conﬁrming a shared hiPSC-MK
identity distinct from cbMKs, the principal component analysis
indicated that LT-fopMKs clustered closer to cbMKs than
fopMKs and ddMKs (Fig. 4f)30. Altogether, the whole-genome
expression analysis validated the acquisition by MK-FOP
of a genuine MK phenotype that was effectively maintained
throughout long-term culture.
In vitro production of functional platelets by fopMKs. Mature
MKs produce platelets by a process of proplatelet formation
whereby MKs extend cytoplasmic protrusions into the bone
marrow blood stream31. These protrusions contain multiple
branching points and bulbous ends with active accumulation of
granules into the end processes that represent the nascent
platelets, which then mature further in the circulation. In culture,
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fopMKs formed proplatelets containing P-selectin-positive
a-granules (Fig. 5a,b; Supplementary Movies 1 and 2). For
further analyses, in vitro platelet production was maximized using
a static co-culture system with the murine C3H10T1/2 feeder cell
line as previously described27. Electron microscopy showed that
platelets produced in vitro from fopMKs and cbMKs, while
heterogeneous in quality reﬂecting the current limitations of 2D
static cultures, showed the typical platelet ultrastructure notably
including high alpha-granule content (Fig. 5c). We further used
ﬂow cytometry for the quantitative measurement of in vitro
platelet production from fopMKs, strictly deﬁning platelets as
CD41aþ /CD42aþ particles of human platelet size (Fig. 5d). A
signiﬁcant increase in platelet production from LT-fopMKs
versus day 20 fopMKs was observed matching platelet release
from cbMKs (5±0.2 versus 0.8±0.2 platelets per MK at day 90
and day 20, respectively; Fig. 5e). The platelet production rate was
similar amongst fopMKs derived from different hiPSC lines
(hiPSC#1–4; Supplementary Fig. 5a). In vitro platelets showed
surface expression of the main thrombocyte receptors including
the GPIIb/IIIa complex (ﬁbrinogen receptor), GPIb and GPIX
(Von Willebrand factor receptor), GPIIa and GPVI (collagen
receptors), some of them with a decreased intensity compared
with donor platelets which has been previously described and
likely originated from the static 37 C in vitro culture conditions
used for production (Supplementary Fig. 5b)20,32. The fopMK
platelets showed a normal mean volume on a clinical Sysmex
blood analyzer (8.6±0.7 ﬂ, n¼ 2, iPSC#1 and #5; Fig. 5f),
and interestingly an increased immature platelet fraction
compared with normal circulating blood (11.6±3% versus
4±1%, respectively; Fig. 5g). Eventually, we assessed fopMK
platelet survival in vivo in immunodeﬁcient NOD scid gamma
(NSG) mice with further splenic macrophage depletion to allow
human platelet maintenance in the circulation33. The fopMK
platelets were readily detected in the circulation for several hours
while showing a shorter half-life than primary donor platelets
(7.1±0.8 h versus 19.7±2.2 h, respectively; Fig. 5h), a result
which was very similar to previously published data (7.5 and
18.3 h, respectively)19 and probably biased by the limitations of
the current static in vitro production systems for the generation of
homogenous populations of genuine resting platelets endowed
with longer circulation half-life. To further distinguish functional
platelets from the heterogeneous in vitro-produced pool, we used
Calcein-AM as a marker of platelet viability and membrane
integrity34. The proportion of Calcein-AM-positive platelets
within fopMK- and cbMK-derived platelet harvest was
32.4±0.8% (n¼ 3; iPSC#1, #5) and 40.1±3.6%, respectively
(n¼ 3) and deﬁned a phenotypically more homogenous
CD41aþ /CD42aþ platelet population similar to control blood
(Supplementary ﬁg. 5c). Hereafter, in vitro generated platelets
were identiﬁed using Calcein-AM staining to compare their
function with donor-derived platelets.
To fulﬁl their haemostatic role, platelets must be able to
sequentially adhere to damaged vessels (using collagen and other
extra-cellular matrix receptors), increase their surface by spreading
(by active remodelling of their cytoskeleton), build-up the thrombus
by aggregation of other platelets (through ﬁbrinogen binding) and
eventually amplify the haemostatic response through degranulation
(granule content release to the surface)35. We ﬁrst compared
adhesion with ﬁbrinogen using a quantitative ﬂow cytometry
assay36. Similarly to platelets generated in vitro from cbMKs, an
increased adhesion to ﬁbrinogen was observed for fopMK-derived
platelets as compared with blood platelets (Fig. 6a). This distinction
may be inherent to the platelet harvest methodology or originate
from intrinsic developmental biological differences of hiPSC and
neonates platelets compared with adult blood platelets37. We
further showed that fopMK-derived platelets spread efﬁciently
upon contact with ﬁbrinogen presenting typical tubulin cytoskeletal
reorganization (Fig. 6b). We then used a ﬂow cytometry approach
to quantitatively measure agonist-induced platelet aggregation38
(Fig. 6c). We showed that in response to agonist stimulation (a
combination of ADP and TRAP), fopMK-derived platelets
efﬁciently aggregated with fresh blood platelets as well as between
themselves with no signiﬁcant difference in aggregation potential as
compared with blood platelets (Fig. 6d,e). Eventually, we performed
thrombus formation in vitro under physiological shear stress as a
high-level assay of integrated platelet functions. To mimic a
transfusion setting, we introduced a deﬁned amount of Calcein-
AM-labelled in vitro-produced platelets or blood platelets from a
transfusion unit into normal or thrombocytopenic fresh human
blood (platelet count o50 109 per litre; spiked platelets at
10 109 per litre; Supplementary Movies 3 and 4). When exposed
to collagen under arterial shear rates (1,600 s 1), fopMK-derived
platelets took part in clot formation similarly to platelets from a
concentrate unit (Fig. 6f,g). We further observed an increase in the
contribution of fopMK platelets to the thrombi in the context of
thrombocytopenic blood (Fig. 6fg; Supplementary Fig. 5d).
Furthermore, P-selectin surface expression was observed in the
platelets participating in the thrombi, thereby proving adequate
degranulation of activated fopMK platelets (Supplementary Fig. 5e).
The validation of fopMK platelet function was ultimately addressed
in vivo using intravital microscopy and laser injury-induced
thrombus formation in the cremaster vasculature of NSG mice39.
The transfusion of 5Eþ 7 Calcein-AM-labelled platelets into mouse
circulation allowed the visualization of human platelet integration
into thrombi with comparable efﬁciencies between donor and
fopMK platelets (1.5±0.2 and 1.4±0.2 platelets per 100mm2
thrombus area respectively, n¼ 16/12; Fig. 6h,i ). Strikingly,
in vitro-produced fopMK platelets showed active participation in
clot formation with visible sequential rolling, binding, thrombus
surface surveying and spreading (Supplementary Movies 5 and 6).
While current systems for in vitro platelet production from
cultured MKs can be further optimized beyond the 2D static
approach used here, platelets produced in vitro from fopMKs
were nevertheless functionally similar to donor-derived platelets
across a range of assays, thereby afﬁrming their suitability and
promise for a host of regenerative medicine research and
therapeutic applications.
Discussion
We describe here forward programming, a novel approach for the
chemically deﬁned large-scale production of MKs from hiPSCs.
We drive MK development by the combined ectopic expression
of three TFs: GATA1, FLI1 and TAL1. These three TFs have well-
documented roles in haematopoiesis, especially in the main-
tenance of early haematopoietic progenitors, red blood cell and
megakaryocyte differentiation40–44. Forced expression of GATA1
or TAL1 alone in haematopoietic progenitors has been shown to
bias differentiation towards MK and erythroid fates45,46, while
FLI1 cooperates with GATA1 to enable MK maturation47. In
addition, TAL1 and FLI1 play an earlier role in the speciﬁcation
of the haematopoietic programme during vertebrate embryonic
development48,49. Accordingly, exogenous expression of TAL1
in hESCs has been reported to promote haematopoiesis
and megakaryopoiesis50,51. More recently, the combinatorial
expression of TAL1 with GATA2 was found to induce an
hemogenic endothelial phenotype biased towards erythro-
megakaryocytic differentiation from hPSCs52. Nevertheless, the
MK-FOP approach described here involving co-expression of the
3-TFs GATA1, FLI1 and TAL1 is unprecedented in regard to its
efﬁciency in rapidly imposing MK progenitor identity to hPSCs
in very stringent MK-speciﬁc culture conditions. The high
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hierarchical status of the 3-TFs within the MK gene regulatory
network, already supported by previously published gene
interaction network and ChIP-sequencing data in primary
human MKs26,53 (Supplementary Fig. 2c), is now functionally
conﬁrmed in human cells by the efﬁciency of the MK-FOP
approach.
It remains to be demonstrated how closely the 3-TF
programming recapitulates normal haematopoietic development
from hPSCs. Current data indicate that mesoderm commitment
is strongly beneﬁcial to MK-FOP, consistent with the normal
ontogeny of blood cells in the embryo. Intriguingly, we observed
an early expression of hemogenic endothelium markers (FLK1,
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CD34 and VE-Cadherin) from day 2 of programming which was
intermingled with expression of the megakaryocyte commitment
marker CD41a and quickly followed by a marker of blood
commitment with the increasing concurrent CD43 expression
from day 3 onwards (Supplementary Fig. 6). The progressive
decrease of endothelial populations associated with a steady TPO-
dependent growth of CD41aþ cells from day 4, as well as the
absence of monocyte/granulocyte colonies in clonogenic assays,
indicates an early commitment to MK fate (Supplementary
Fig. 6). Taken together, these observations suggest that over-
expression of the 3-TFs in hPSCs may at least partially
recapitulate key steps of the blood ontogeny with a contracted
hemogenic endothelium phase and early enforcement of MK
identity. Controllable and traceable 3-TF expression systems
combined with molecular analysis at the single-cell level will be
necessary to further decipher the precise molecular mechanisms
governing MK-FOP.
There is high biotechnological signiﬁcance in our ability to
maintain the forward programmed cells in long-term cultures
and expand them over time whilst preserving MK purity,
markers of maturity and platelet production. This TPO- and
SCF-dependent cellular proliferation persisted for an extended
but not indeﬁnite timeframe (90–134 days) and is presumably
sustained by non-transformed early MK-biased progenitors
(o1% by CFU assays) able to proliferate and differentiate further
towards mature MKs. In this respect the LT-fopMK culture
appears different in nature to the recently described expandable
MK cell lines obtained from hPSCs by sequential ectopic
introduction of MYC, BMI1 and BCL-XL into MK-committed
cells20. The generation of these MK cell lines notably requires the
precise control of MYC expression levels and subsequent
silencing of those three overexpressed genes to achieve full MK
maturation. The complex genetic modiﬁcations involved and the
limited success rate of immortalized MK line derivation—
involving manual screening and clonal selection—along with
the initial generation of blood progenitors in undeﬁned
conditions are limitations of that protocol for both research
and clinical development. MK-FOP did not produce an
immortalized MK progenitor and did not require manipulation
of gene expression levels to produce fully mature MKs.
Interestingly, MK lineage biased self-renewing progenitors
have been recently identiﬁed in the haematopoietic stem cell
phenotypic compartment of the bone marrow54. Further
investigations are needed to understand the full nature and the
3-TF-driven molecular mechanisms underpinning the generation
of this long-term expanding MK progenitor.
Recently, another approach has been published that allows the
expansion of MK progenitors derived from PSCs55. In contrast
with MK-FOP, that system is based on the artiﬁcially controlled
downregulation of GATA1 in haematopoietic progenitors
allowing MK progenitor expansion and its restoration to enable
subsequent MK maturation. The approach, which was developed
with mouse ESCs, has yet to be demonstrated to work in human
cells. In addition, the authors did not show efﬁcient platelet
production from these MKs in vitro, instead choosing an adoptive
transfer of MKs into recipient mice. The injection of nucleated
cells derived from human pluripotent stem cells would raise
crucial issues of potential tumorigenicity that could constrain
future clinical use.
The quantitative functional platelet data collected here proved
that platelets derived from fopMKs in vitro are endowed with
major platelet functions allowing efﬁcient thrombus formation as
shown in previous studies19,20. Although abnormalities in key
TFs for the MK lineage can lead to abnormal platelet function43,
the preservation of fopMK platelet function is consistent with the
fact that the overall expression levels of the 3-TFs is controlled
throughout the programming progression and similar to cbMKs.
The remaining bottleneck for application to transfusion medicine
is the optimization of platelet generation in vitro: this presently
remains on average 1,000-fold lower than the in vivo platelet yield
per MK and is accompanied by issues regarding the purity of the
ﬁnal product where functional platelets represent only a fraction
of the platelet size particles in the whole harvest19,20,56. In this
study, which focuses on the production of the MKs themselves,
we have used a previously published platelet production system
based on co-culture with a mouse stromal cell line27,57. Our
ﬁndings clearly confer an impetus to achieve further progress
using newly developed three-dimensional laminar ﬂow systems
and bone marrow mimicking scaffolds58–60 by providing ample
quantities of functional MKs from hPSCs using a simpliﬁed
chemically deﬁned protocol amenable to the generation of a
clinical product.
In conclusion, our study demonstrates the feasibility of a
forward programming approach to generate mature functional
MKs from human PSCs that signiﬁcantly transcends available
directed differentiation protocols through a unique combination
of key achievements. First, the methodology results in a very high
cell yield and MK purity using fully chemically deﬁned xeno-free
culture conditions. To put this in the clinical context, the
long-term culture expansion allows a cumulative production of
2 1011 MKs releasing 1 1012 platelets—the equivalent of
3 transfusion units—starting from only one million hiPSCs.
Figure 6 | Functional assessment of fopMK in vitro platelets. (a) Adhesion to ﬁbrinogen of fopMK and cbMK in vitro platelets upon combined TRAPþADP
stimulation compared to blood platelets using a ﬂow cytometry bead based assay. Percentages of adhesion on BSA or ﬁbrinogen-coated beads are shown
(mean±s.e.m., n¼4, 4, 2 for blood, fopMK and cbMK respectively; **Po0.01 versus blood by two-tail t-test). (b) Representative pictures from in vitro
spreading assay. Washed platelets were sown on ﬁbrinogen-coated slides, incubated for 45 min at 37 C and immunostained for alpha-tubulin (TUBA) and
F-actin (scale bars, 10mm). (c) Aggregation of fopMK platelets upon agonists stimulation was tested both with and compared with blood platelets using a ﬂow
cytometry-based assay: representative dot plots are shown. (d) Percentages of aggregation from Calcein-AMþ live platelets upon stimulation are shown for
blood and fopMK platelets reactions (2 107 platelets per ml; mean±s.e.m., n¼ 7 for each reaction group; no statistical difference versus blood at Po0.01 by
two-tail t-test). (e) Associated delta-aggregation deﬁned as ((% ADPþTRAP aggregation)—(% no agonist aggregation)) for the different reaction groups
(mean ±s.e.m., n¼ 7; P values by two-tail t-test versus blood indicated). (f) Thrombus formation in vitro under arterial shear stress. The participation of
Calcein-AM live platelets spiked into human blood (at 1 107 per ml) is shown per 100mm2 thrombus area. Normal or thrombocytopenic blood (4150 109
and o50 109 l 1 respectively) was used as recipient. Spiked platelets were sourced from day-8 concentrate unit (blood) or from fopMK platelets
(iPSC#1 and #5; n430 analysed thrombi per group; P values by two-tail t-test versus blood indicated). (g) Representative pictures from in vitro thrombus
formation assays. Thrombi identiﬁed using bright ﬁeld images are delineated and Calcein-AM platelets ﬂuorescing in green; in vitro platelets Calcein-AM
labelling is intrinsically dimmer than donor-derived platelets (Supplementary Fig. 5b). Scale bar, 50mm. (h) Thrombus formation in vivo by laser injury of an
arteriole in the cremaster muscle of NSG mice and intravital confocal microscopy. The incorporation of human Calcein-AM-labelled platelets (50 million
transfused per mouse) to mouse thrombi is shown per 100mm2 thrombus area at T_max (thrombus maximum size). Mean values±s.e.m. and P values by
two-tail t-test versus donor platelets are shown (n¼ 16/4/8 thrombi analysed for blood, fopMK#1 and #5 platelets respectively). (i) Representative snapshots
of Calcein-AMþ human platelets incorporated to mouse thrombus (scale bar 10mm).
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Moreover, the minimal cell handling and cytokine requirements,
the cryopreservation of fopMKs enabling cell banking and future
stock management and the successful differentiation of an array
of hPSC lines with qualitative reproducibility are additional
critical strengths of the MK-FOP approach for future manufac-
turing of platelets for human therapeutic applications. The
effectiveness and versatility of MK-FOP opens new avenues for
future basic research and functional studies on novel MK and
platelet genes as well as disease modelling using hiPSCs53,61,62.
Methods
Human pluripotent stem cell culture. The H9 hESC line (WiCell; passages
75–95) and hiPSC lines (iPSC#1–5; A1ATD1, BBHX8, A1ATD1-c, S4-SF5 and
FFDK1, respectively, p30–50) were cultivated as clumps in a chemically deﬁned
medium (CDM) containing recombinant human FGF2 and Activin-A (15 ngml 1
each, internal) on feeder-free gelatin or vitronectin coated wells as previously
described63. All hiPSC lines were obtained from the Cambridge Biomedical
Research Centre iPSC Core Facility and have been derived from adult dermal
ﬁbroblasts using integrative murine retroviral vectors (iPSC#1–2), cytoplasmic
Sendai viral vectors (iPSC#3–4) or episomal vectors (iPSC#5) expressing the
human OCT4, SOX2, KLF4 and MYC reprogramming factors.
Selection of transcription factor candidates. We performed a differential gene
expression analysis focused on DNA binding protein coding genes (PANTHER
Classiﬁcation System) from whole-genome expression data generated using the
H9 hESC line (internal data, Illumina HumanWG-6 v3) and human cord
blood-derived MKs23. The list of 116 MK-speciﬁc genes generated was further
reﬁned by removal of 21 histone-coding genes and addition of 6 candidates based
on previous knowledge of their role in megakaryopoiesis (Supplementary Fig. 1a).
Using the VisANT web-based software24, the resulting 101 candidate genes
were subsequently ranked based on number of (1) internal protein interactions,
(2) interaction with epigenetic modiﬁers (HAC, HDAC, DNMT, list in
Supplementary Fig. 1c) and (3) differential expression levels (Supplementary
Fig. 1b). Genes with low differential expression (Log2(MK-ESC)o1 or o2
with no reported interactions) were excluded from the candidate list.
Recombinant lentiviral vectors. Transcription factor cloning. The human coding
sequences of the nine candidate genes (variants 1 from NCBI Reference Sequence
Database) including the 50 Kozak consensus sequence were generated by PCR using
cbMK cDNA, individually cloned into the pWPT lentiviral vector backbone
(Dr Trono, Addgene #12255) downstream of the human EF1-alpha ubiquitous
promoter and checked for sequence integrity.
Viral particle production. Replication deﬁcient lentiviral vector particles (LVPs)
were produced by transient co-transfection of HEK 293T/17 cells (ATCC
CRL-11268) with pWPT constructs along with the psPAX2 and pMD2.G helper
plasmids (Addgene #12260, #12259) using TransIT-LT1 transfection reagent
(MirusBIO). Crude supernatants containing LVPs were concentrated by
PEG-based precipitation (LentiX-concentrator, Clontech) and functional titres
determined by qPCR measurement of provirus copy number in genomic
DNA of transduced HCT116 cells (ATCC CCL-247).
Human pluripotent stem cell transduction. hPSC lines were routinely transduced
by 18–24 h single exposure to LVPs using multiplicity of infection of 20 in presence
of 10 mgml 1 Protamine Sulfate (Sigma) in routine culture medium.
Megakaryocyte forward programming. Optimized embryoid body based protocol.
On transduction day (day 0), sub-conﬂuent (50–80%) hPSC cultures were
dissociated to single cells using TrypLE (Life Technologies) Fig. 2a. Embryoid body
formation was initiated with 6–12Eþ 5 viable cells per well of an Aggrewell400
plates (Stem Cell Technologies) leading to 500–1,000 cells per embryoid body
following spin aggregation. Lentiviral transduction was performed concomitantly
to the aggregation step in CDM supplemented with Y-27632 (10 mM, Sigma),
BMP4 (10 ngml 1, R&D) and protamine sulfate. After 24 h, transduced embryoid
bodies were collected and sown in ultralow adherent cell culture plates (Corning)
at 1,200 embryoid bodies per 10 cm2 dish in CDM with BMP4 and FGF2
(5 ngml 1). Twenty-four hours later, embryoid bodies were washed and sown in
ultralow adherent plates at 600 embryoid bodies per 10 cm2 in CellGroSCGM
medium (CellGenix) supplemented with TPO (100 ngml 1, Cellgenix) and SCF
(25 ngml 1, Gibco). At day 10, embryoid bodies were dissociated to single cells
using Collagenase-IV and Dispase-II (1mgml 1, Gibco) followed by enzyme free
cell dissociation buffer (Gibco) treatment. Single cells were cultivated at 2Eþ 5 per
ml on tissue culture plates (Corning) for an additional 10 days in CellgroSCGM
with TPO (100 ngml 1) and IL1-b (10 ngml 1, Miltenyi Biotec). Half of culture
media was renewed every 3 days.
Long-term MK-FOP cultures. From day 10 after dissociation to single cells,
the cultures were maintained in CellGroSCGM with low TPO concentration
(20 ngml 1) and SCF (50 ngml 1). Culture medium was half-renewed every 3
days and cells split every 7–10 days when reaching concentration of 1–1.5Eþ 6
cells per ml.
FOPMK freezing. Cells from day 30–70 cultures were collected and frozen at
0.5–2Eþ 6 cells per ml in IMDM 20% fetal bovine serum (Gibco) and 5% DMSO
(Sigma).
Adherent cell protocol. Small cell clumps were generated from sub-conﬂuent
hPSC cultures using a Collagenase-IV and Dispase-II mix and sown on human
ﬁbronectin coated (50mgml 1, Millipore) wells in CDM-containing FGF2 and
Activin-A (15 ngml 1 each) at an approximate density of 2–5Eþ 5 cells per
10 cm2. Cells were transduced with LVPs the next day and kept for 2 days in
FGF2þActivin-A (pluripotency) or FGF2þ LY-294002þBMP4 (ref. 25)
(mesoderm) depending on experiment settings. From day 2, cells were
maintained in CellgroSCGM with TPO and SCF as described above.
MK-directed differentiation. hPSC lines were differentiated as described27 using
batch tested serum and stromal cells from Prof Koji Eto Laboratory.
Cord blood-derived megakaryocytes. Cord blood was obtained after informed
consent under a protocol approved by the Cambridgeshire 4 Research Ethics
Committee (07/MRE05/44). CD34-positive cells (Z98%) isolated by magnetic cell
sorting (Myltenyi Biotec) were seeded at 1Eþ 5 cells per ml in CellgroSCGM
containing TPO (100 ngml 1) and IL1-b (10 ngml 1) and cultivated for 10 days.
We routinely obtained 70–90% CD41aþ and 20–60% CD42aþ cells by the end of
the culture.
Flow cytometry analysis. Flow cytometry experiments were performed on a
CyAn ADP (Beckman Coulter). Single-cell suspensions were generated using a
Collagenase-IV/Dispase-II mix and/or enzyme free dissociation buffer. Cells were
stained for 20 min at room temperature (RT) in PBS 0.5%BSA 2mM EDTA using
combinations of FITC, PE and APC-conjugated antibodies (Supplementary
Table 1). Background ﬂuorescence was set against matched isotype control anti-
bodies and compensation matrix deﬁned using single-colour-stained cells. Flow
count ﬂuorospheres (Beckman Coulter) and DAPI (1 mgml 1) were used to
determine viable cell count in samples.
Cell morphology and phenotype analysis. Cell morphology analysis. Cells were
spun onto a glass slide using cytofunnels at 400g for 5 min, methanol ﬁxed and
stained using the Romanowsky method.
Megakaryocyte colony forming assay. Around 5,000 cells per chamber were used
in MethoCult methylcellulose assays (#4230, StemCell Technologies) containing
screened fetal bovine serum and supplemented with TPO and SCF (100 and
50 ngml 1 respectively); MegaCult collagen cultures (StemCell Technologies)
were dehydrated following manufacturer’s instructions for colony immunostaining.
Immunoﬂuorescence analysis. Megakaryocytes were cultivated on human
ﬁbrinogen (50 mgml 1, Millipore) coated glass cover slips for 48 h to foster
adhesion and proplatelet formation. Cells were ﬁxed in 2% formaldehyde,
permeabilized with 0.1% Saponin/0.2% Gelatin and incubated 2 h at RT with
selected primary antibodies (Supplementary Table 1) then with ﬂuorochrome
conjugated secondary antibodies for 45 min atRT. Cell nuclei were stained with
DAPI. Images were acquired on a ﬂuorescent microscope Axiovert 40 (Zeiss) or a
SP5 confocal microscope for granule imaging (Leica).
Ploidy analysis. Cells were ﬁxed using 4% formaldehyde for 10 min at RT,
immunostained for CD41a and CD42a expression and subsequently incubated in
PBS 0.1% Tween with DAPI at 1 mgml 1 for 15 min at RT before ﬂow cytometry
analysis.
Transmission electron microscopy. Megakaryocytes were ﬁxed in 2%
glutaraldehyde/formaldehyde followed by post ﬁxation, resin embedding and
staining as previously described17,64, and eventually analysed on a FEI Tecnai G2
microscope.
Gene expression analysis by RT-qPCR. Total RNA was extracted using RNeasy
kits (Qiagen) according to the manufacturer’s instructions including DNase
treatment. cDNA was prepared from 250–500 ng total RNA using Maxima First
Strand cDNA Synthesis Kit (random hexamers and oligo(dT)18 mix for priming;
Fermentas). Two-step qPCR reactions were performed in duplicates using SYBR
green chemistry on ABI 7500HT or Mx3000P instruments (Applied Biosystems;
Agilent Technologies). Relative gene expression was calculated by the 2Dct
method using HMBS as housekeeping gene for normalization. qPCR primer pairs
(Supplementary Table 2) designed to amplify only cDNA, to detect all known
isoforms, and to have no reported off-target matches searching the human
NCBI RefSeq database were tested within 80–120% PCR efﬁciencies with single
dissociation curves. We used UTR targeting (absent from transgenes) to monitor
endogene expression while transgene speciﬁc primer pairs used a common reverse
primer speciﬁc to the viral vector RNA.
Whole-genome expression microarray analysis. DNA-free total RNA was
extracted as above from sorted CD42bþ cell fractions using the EasySep system
(Stemcell Technologies; 495% purity, for cbMK, ddMK and fopMK samples) or
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unsorted 480% CD42bþ cells (LT-fopMK samples) and 500 ng hybridized to
Illumina Human HT-12 v4 BeadArrays.
Microarray gene expression. Microarray signal intensities from Genome Studio
version1.9 were variance stabilization transformed and robust spline normalized
(RSN). For differential analysis, we removed low signal probes with detection
P value40.01 in all samples, leaving only informative probes. These procedures
were carried out using R package Lumi. For each pairwise differential analysis,
we applied surrogate variable analysis (SVA) to correct for un-modelled factors
that may bring about batch effects. We then tested for differential expression using
limma where statistical signiﬁcance was set to 2-fold change and 5% false discovery
rate or Benjamini-Hochberg adjusted P value.
Hierarchical clustering. Hierarchical clustering was performed using R package
pvclust. For dissimilarity or distance measure, we use 1-correlation and average as
agglomerative method.
Gene ontology enrichment analysis. We performed enrichment analysis using
GOstat 2.24 of over-represented gene ontology terms in the set of differentially
expressed genes. We used standard hypergeometric test using only informative
probes in the chip as the universe.
Gene set enrichment analysis. We used gsea2–2.0.13 with datasets for
megakaryocytes (n¼ 4) and other blood cells (n¼ 46) from the Haematlas
study23 (E-TABM-633; Illumina Human-6v2 array).
Principal component analysis. Classiﬁcation of samples in multiple dimensional
factor spaces was applied by calling the function cmdscale.
Gene expression heatmaps. Heatmap builder v1.1 (Dr Ashley lab, Stanford) was
used for dataset normalized representations.
In vitro platelet analysis. Co-culture on feeder cells. To promote platelet
production, day 10 cbMKs and day 20–90 fopMKs were further cultivated for 48 h
in CellgroSCGM plus Heparin (25Uml 1) without further cytokine addition at
1Eþ 5 cells per cm2 on gamma-irradiated C3H10T1/2 feeder cells (Riken Institute;
1Eþ 4 cells per cm2).
Platelet ﬂow analysis. Crude supernatant containing the platelets was analysed
by ﬂow cytometry after addition of 1:9 volume of acid citrate dextrose (ACD,
Sigma) and cell removal by centrifugation 150g at 10 min. Antibodies against
human platelet receptors were added directly to the media (1:50 dilution, see
Supplementary Table 1) for 30 min at RT and unwashed platelets analysed using
ﬂuorospheres for quantiﬁcation. Human platelets from fresh whole-blood diluted
in PBS/ACD or from day 8–10 platelet concentrate units (NHSBT, UK) were
analysed in parallel.
Washed platelet preparation. Human platelet-rich plasma and in vitro generated
platelets collected as above were washed following the optimized protocol
from Cazenave et al.65 to prevent activation and maximize platelet function
preservation.
Platelet size analysis. Washed platelets were run on a Sysmex XE-2100 Automated
Hematology System.
Electron microscopy. Washed platelets were ﬁxed and stained as described
for MKs.
Spreading assay. Washed platelets in Tyrode-HEPES buffer complemented with
CaCl2 1mM were sown on ﬁbronectin coated glass cover slips and incubated
45 min at 37 C. They were subsequently ﬁxed using 2% formaldehyde,
immunostained and analysed as described for MKs.
Platelet survival in vivo. Washed platelets were injected to macrophage depleted
(by clodronate liposome injection at day  3) 8–12-week-old male NOD scid
gamma (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ; NSG) mice through the tail vein as
single dose of 2Eþ 7 CD41a/42aþ þ platelets. The human versus mouse platelet
content was monitored by ﬂow cytometry from whole-blood samples at 1, 30,
120min and 24 h after transfusion using antibodies speciﬁc for human and murine
CD41a. The absolute human platelet count was determined using ﬂow count
ﬂuorosphere (Beckman Coulter) and platelet survival calculated by the multiple
hits method relative to the 30min equilibrium time point66,67. All mice were kept
in speciﬁc pathogen-free conditions, and all procedures were performed according
to the United Kingdom Home Ofﬁce regulations and approved by the University of
Cambridge Animal Welfare Ethical Review Body.
In vitro thrombus formation in laminar ﬂow. Human blood or in vitro platelets
were stained with Calcein-AM (100 nM; Life Technologies) for 10 min at 37 C
before being washed and deﬁned amount were mixed with 1ml of human blood
collected in 3.2% Citrate. Thrombocytopenic blood was artiﬁcially prepared by
depleting the platelets from plasma by performing 2 sequential centrifugation steps
at 2,200g for 10 min and washing the red blood cell fraction with Tyrode-HEPES
buffer before blood reconstitution. The procedure for clot formation under ﬂow
was modiﬁed from de Witt et al.68 Brieﬂy, glass slides were locally coated with
Horm collagen spots (50 mgml 1) and mounted into a ﬂow chamber placed under
a ﬂuorescent microscope (EVOS system, Advanced Microscopy Group). The blood
was then perfused through the chamber at 1,600 s 1 (7.2ml h 1) for 3min
allowing thrombi formation on collagen spots and imaging subsequently
performed. Image analysis was carried on using ImageJ recording thrombus area
and calcein-AM events per clot.
Thrombus formation intravital imaging. Washed platelets were labelled with
Calcein-AM and injected to macrophage depleted 8–12-week-old male NSG mice
through the carotid artery after cannulation as single dose of 5Eþ 7 CD41a/42a/
Calcein-AMþ þ þ platelets. Thrombus formation was induced from 15min
onwards after platelet transfusion by micropoint laser injury of the cremaster vessel
walls as previously described39. Fluorescent and bright ﬁelds were simultaneously
recorded by confocal microscopy and analysed using SlideBook 6 (Intelligent
Imaging Innovations). The number of Calcein-AMþ human platelets
incorporated in mouse thrombi until maximal size was reached was recorded and
reported to thrombus area. All animal experiments have been approved by the
United Kingdom Home Ofﬁce and the Birmingham University Animal Welfare
Ethical Review Body.
Flow cytometry aggregation assay. Modiﬁed from original protocol38 to include
the live–dead particle discriminator Calcein-AM, it allows quantiﬁcation of platelet
aggregation using small numbers of platelets (2Eþ 6 per reaction). Duplicate
platelet samples were stained with Calcein-AM and anti-CD31 (clone WM59)
conjugated with APC or V450 in HEPES buffer supplemented with 20 mM PPACK
dihydrochloride (Calbiochem), washed then mixed in the presence or absence of
the agonists thrombin receptor-activating peptide (TRAP) and ADP (10 mM each).
Percentage aggregation was determined by ﬂow cytometry for Calcein-AM-positive
double CD31-positive events.
Bead platelet adhesion ﬂow cytometry assay. Modiﬁed from original protocol36,
it quantiﬁes adhesion of platelets to single 20mM polystyrene beads (Sigma) coated
with either BSA or Fibrinogen. 3 105 platelets stained with 100 nM Calcein-AM
were mixed in basal culture media with either 20 ml BSA or 20ml ﬁbrinogen-coated
beads, agonists (TRAP and ADP as above), incubated for 10’/37 C and
subsequently stained with anti-CD41a-APC antibody. DAPI negative, Calcein-AM
and CD41a positive single beads bound by platelets are quantiﬁed by ﬂow
cytometry.
Statistics. Results are presented as mean±standard error of the mean (s.e.m.)
with n representing the number of biological replicates unless otherwise stated.
Statistical P values were calculated by two-tail Student’s t-test unless otherwise
stated.
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